134 related articles for article (PubMed ID: 18520515)
1. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
Foerster CG; Cursiefen C; Kruse FE
Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
[TBL] [Abstract][Full Text] [Related]
2. [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment].
Förster CG; Cursiefen C; Kruse FE
Ophthalmologe; 2008 Mar; 105(3):269-73. PubMed ID: 18350301
[TBL] [Abstract][Full Text] [Related]
3. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
Bambury R; McCaffrey JA
Clin Colorectal Cancer; 2009 Oct; 8(4):235. PubMed ID: 19822516
[No Abstract] [Full Text] [Related]
4. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Rodriguez NA; Ascaso FJ
J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
[No Abstract] [Full Text] [Related]
5. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
6. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
8. [Dry eye].
Cursiefen C
Ophthalmologe; 2013 Jun; 110(6):498-9. PubMed ID: 23783991
[No Abstract] [Full Text] [Related]
9. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
Cohen PR; Escudier SM; Kurzrock R
Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-associated pulmonary toxicity.
Chua W; Peters M; Loneragan R; Clarke S
Clin Colorectal Cancer; 2009 Apr; 8(2):118-20. PubMed ID: 19739274
[TBL] [Abstract][Full Text] [Related]
11. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Zhang G; Basti S; Jampol LM
Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
[TBL] [Abstract][Full Text] [Related]
12. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh F; Kurzrock R; Johnson FM
J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
[No Abstract] [Full Text] [Related]
13. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
Gencoglan G; Ceylan C
Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
[TBL] [Abstract][Full Text] [Related]
14. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing.
Hori K; Sotozono C; Hamuro J; Yamasaki K; Kimura Y; Ozeki M; Tabata Y; Kinoshita S
J Control Release; 2007 Apr; 118(2):169-76. PubMed ID: 17289206
[TBL] [Abstract][Full Text] [Related]
15. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
[No Abstract] [Full Text] [Related]
16. Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.
Koksal UI; Pilanci KN; Ordu C; Okutur K; Saglam S; Demir G
Am J Ther; 2016; 23(5):e1226-9. PubMed ID: 26079631
[TBL] [Abstract][Full Text] [Related]
17. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
Saif MW; Gnanaraj J
Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-induced hypertrichosis of the scalp and eyelashes.
Vano-Galvan S; Ríos-Buceta L; Ma DL; Fernández-Chacón C; Viera JC; Jaén P
J Am Acad Dermatol; 2010 Mar; 62(3):531-3. PubMed ID: 20159332
[No Abstract] [Full Text] [Related]
20. Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody.
Kerob D; Dupuy A; Reygagne P; Levy A; Morel P; Bernard BA; Lebbé C
Arch Dermatol; 2006 Dec; 142(12):1656-7. PubMed ID: 17179005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
